Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
  • A61L27/28—Materials for coating prostheses
  • A61L27/34—Macromolecular materials
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
  • A61L31/08—Materials for coatings
  • A61L31/10—Macromolecular materials
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L2420/00—Materials or methods for coatings medical devices
  • A61L2420/08—Coatings comprising two or more layers

Definitions

• Polymers are generally characterized by their bulk properties such as tensile strength, yield stress, hardness, stiffness, elongation and gas permeability. Manufacturers use these properties to determine whether a particular polymer might be useful in a particular application. If, for example, a material that is hard and impact resistant is required, for use in say motorcycle helmets, a polymer that exhibits those bulk properties will be selected. If the intended use requires flexibility, toughness and elongation, as might be case with expandable coronary stents, a different type of polymer will be chosen.
• Polymer characteristics are affected by the monomer types and composition, the polymer architecture and the molecular weight.
• the crystallinity of the polymer varies with the stereoregularity of the polymer.
• racemic D, L poly(lactide) or poly(glycolide) is less crystalline than the D or L homopolymers.
• Poly(lactide) (PLA) and its copolymers having less than 50% glycolic acid content are soluble in common solvents such as chlorinated hydrocarbons, tetrahydrofuran and ethyl acetate while poly(glycolide) (PGA) is insoluble in common solvents but is soluble in hexafluoroisopropanol.
• the bulk properties of polymers can, however, change with time, a process known as aging. Aging can render a polymer unsuitable for its originally intended purpose and possibly cause a construct comprising that polymer to fail in use.
• Polymers age by physical, chemical and/or electrical processes. Chemical aging results from exposure of a polymer to external factors such as air (oxygen), moisture, solvents, radiation, heat and light. Electrical aging results from voltage- induced stress that occurs at voltages usually in excess of about 3 kilovolts. Physical aging, which is the primary focus of this invention, results from residual and applied stresses.
• DESs drug- eluting stents
• the efficacy of DESs is related to their ability to release drugs in a controlled manner.
• a rate-controlling layer e.g., a topcoat layer, that is disposed over a drug reservoir layer and which comprises one or more polymers selected for their ability to mediate release of a particular drug or drugs from the underlying reservoir layer.
• Another way to control drug release from a stent is by putting drugs in a drug reservoir layer that includes a polymeric matrix that mediates the release rate of the drug. Indeed, by manipulating the drug-to-polymer ratio, drug release can be controlled.
• the choice of polymer greatly affects the release of drugs from the device as well as the long term stability of the polymer on the device. What is needed, therefore, is a method of mitigating the aging process of polymers so as to extend the useful life of coated medical devices as well as add an additional level of control over release rates of drug eluting devices.
• the present invention provides coatings that solve these and other problems in the art.
• the present invention relates to an implantable medical device that includes a device body and a coating comprising a stereocomplex of poly(D-lactic acid) (PDLA) and poly(L-lactic acid) (PLLA) disposed over the device body, wherein the coating can form a primer layer, a reservoir layer, a topcoat layer or any combination thereof.
• the device body can be a stent.
• the coating can form a primer layer disposed over the device body.
• the coating can form a reservoir layer disposed over the device body.
• the reservoir layer can include one or more bioactive agents.
• the coating can form a top-coat layer disposed over a reservoir layer.
• the reservoir layer can be formed from the coating.
• Another aspect of the present invention relates to a method for increasing the stability of an implantable medical device coating that involves providing a device body and disposing a coating comprising a stereocomplex of poly(D-lactic acid) and poly(L-lactic acid) over the device body.
• the device body can be a stent.
• implantable medical device refers to any type of appliance that is totally or partly introduced, surgically or medically, into a patient's body or by medical intervention into a natural orifice, and which is intended to remain there after the procedure.
• the duration of implantation may be essentially permanent, i.e., intended to remain in place for the remaining lifespan of the patient; until the device biodegrades; or until it is physically removed.
• implantable medical devices include, without limitation, implantable cardiac pacemakers and defibrillators, leads and electrodes for the preceding, implantable organ stimulators such as nerve, bladder, sphincter and diaphragm stimulators, cochlear implants, prostheses, vascular grafts, self- expandable stents, balloon-expandable stents, stent-grafts, grafts, PFO closure devices, arterial closure devices, artificial heart valves and cerebrospinal fluid shunts.
• implantable organ stimulators such as nerve, bladder, sphincter and diaphragm stimulators
• cochlear implants prostheses, vascular grafts, self- expandable stents, balloon-expandable stents, stent-grafts, grafts, PFO closure devices, arterial closure devices, artificial heart valves and cerebrospinal fluid shunts.
• device body refers to a fully formed implantable medical device with an outer surface to which no coating or layer of material different from that of which the device itself is manufactured has been applied.
• Outer surface means any surface, however spatially oriented, that is in contact with bodily tissue or fluids.
• An example of a “device body” is a BMS, i.e., a bare metal stent, which is a fully-formed usable stent that has not been coated with a layer of any material different from the metal of which it is made. It is to be understood that device body refers not only to BMSs but also to any uncoated device regardless of what it is made.
• stents refers generally to any device used to hold tissue in place in a patient's body.
• Particularly useful stents are those used for the maintenance of the patency of a vessel in a patient's body when the vessel is narrowed or closed due to diseases or disorders including, without limitation, tumors (in, for example, bile ducts, the esophagus or the trachea/bronchi), benign pancreatic disease, coronary artery disease, carotid artery disease, renal artery disease and peripheral arterial disease such as atherosclerosis, restenosis and vulnerable plaque.
• a stent can be used to strengthen the wall of the vessel in the vicinity of a vulnerable plaque (VP).
• VP refers to a fatty build-up in an artery thought to be caused by inflammation.
• the VP is covered by a thin fibrous cap that can rupture leading to blood clot formation.
• a stent can not only maintain vessel patency but can act as a shield against VP rupture.
• a stent can be used in, without limitation, neuro, carotid, coronary, pulmonary, aortic, renal, biliary, iliac, femoral and popliteal as well as other peripheral vasculatures.
• a stent can be used in the treatment or prevention of disorders such as, without limitation, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, chronic total occlusion, claudication, anastomotic proliferation, bile duct obstruction and ureter obstruction.
• disorders such as, without limitation, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, chronic total occlusion, claudication, anastomotic proliferation, bile duct obstruction and ureter obstruction.
• a stent used for patency maintenance is usually delivered to the target site in a compressed state and then expanded to fit the vessel into which it has been inserted. Once at a target location, a stent may be self-expandable or balloon expandable. Due to the expansion of the stent, however, a stent coating must be flexible and capable of elongation.
• stent materials include, without limitation, stainless steel, nitinol, tantalum, tantalum alloy, titanium, titanium alloy, cobalt chromium, alloy x, niobium, niobium alloy, zirconium and zirconium alloy.
• Implantable medical devices of the invention e.g., stents, will include a coating that comprises a stereocomplex of PDLA and PLLA disposed over the device body.
• stereocomplex refers to a polymer structure comprising individual PDLA and PLLA polymer chains connected supra-molecularly.
• sodium-molecular interactions refer to noncovalent interactions between chemical groups on different polymer chains.
• stereocomplex can also refer to a stereoselective interaction between two complementing stereoregular polymers, that interlock and form a new composite, demonstrating altered physical properties in comparison to the parent polymers.
• a material that is described as a layer "disposed over" an indicated substrate refers to a relatively thin coating of the material applied directly to essentially the entire exposed surface of the indicated substrate.
• the term “disposed over” may, however, also refer to the application of the thin layer of material to an intervening layer that has been applied to the substrate, wherein the material is applied in such a manner that, were the intervening layer not present, the material would cover substantially the entire exposed surface of the substrate.
• primer layer refers to a coating consisting of a polymer or blend of polymers that exhibit good adhesion characteristics with regard to the material of which the device body is manufactured and good adhesion characteristics with regard to whatever material is to be coated on the device body.
• a primer layer is applied directly to a device body to serve as an intermediary layer between the device body and materials to be affixed to the device body.
• primers include silanes, titanates, zirconates, silicates, parylene, vinyl alcohol copolymers, acrylic acid copolymers, methacrylic acid copolymers, polyethyleneamine, polyallylamine, acrylate and methacrylate polymers with poly(n-butyl methacrylate).
• the primer layer can include a stereocomplex of the invention.
• reservoir layer refers either to a layer of one or more bioactive agents applied to a medical device neat or to a layer of polymer or blend of polymers that has dispersed within its three-dimensional structure one or more bioactive agents.
• a polymeric reservoir layer is designed such that, without limitation, by elution or as the result of biodegradation of the polymer, the bioactive agent is released from the layer into the surrounding environment.
• the reservoir layer generally comprises a biocompatible polymer that can be biostable or biodegradable and can be hydrophobic or hydrophilic. Suitable polymers are known to those skilled in the art.
• the reservoir layer can include a stereocomplex of the invention.
• a rate-controlling layer may be used simply to "tune" the rate of release to exactly that desired by the practitioner or it may be a necessary adjunct to the construct because the polymer or blend of polymers with which the bioactive agent is compatible, with regard to coating as a drug reservoir layer, may be too permeable to the bioactive substance resulting in too rapid release and delivery of the bioactive substance into a patient's body.
• the term "top-coat layer” also refers to an outermost layer that is in contact with the external environment and that is disposed as the final layer of a series of layers. In some presently preferred embodiments of the invention, the topcoat layer can include a stereocomplex of the invention.
• an implantable medical device of the invention will necessarily include a stereocomplex of PDLA and PLLA in at least one of the coating layers, although any combination is encompassed by the present invention.
• the primer layer "pi”, reservoir layer “rl” and topcoat layer “tl” can all be comprised of a stereocomplex of the invention, depicted by pi + rl + tl.
• the determination of which layer or layers will include a stereocomplex of the invention, however, will be left to the practitioner. No matter which layer design is used by a practitioner, a stereocomplex of
• PDLA and PLLA coated onto a device will exhibit a higher Tg and Tm than either homopolymers or copolymers of PDLA and/or PLLA, and thus will exhibit increased stability with improved mechanical properties.
• a stent coated with such a stereocomplex therefore, will be less prone to physical aging since the coating will be quasi-crystalline.
• a coating comprising a stereocomplex will have less variation in subsequent agent release rates.
• Solvents which can be used to dissolve polymers for formation of stereocomplexes include, without limitation, dioxane, chloroform tetrahydrofuran, ethyl acetate, acetone, N-methylpyrrolidone, ethyl and methyl lactate, ethyl acetate and mixtures of these solvents, and other solvents, such as water, short chain alcohols and carboxylic acids (5 carbon atoms or less).
• the particle size of the precipitate is controlled by the selected solvent, the drug, polymer concentrations and the reaction conditions (temperature, mixing, volume etc.), all of which will be ascertainable without undue experimentation by those skilled in the art.
• Bioactive agents of the invention can be incorporated onto or into the stereocomplexes. They can be coupled to the stereocomplexes by ionic, hydrogen or other types of bond formation, including covalent bond formation.
• the bioactive agent can be incorporated into the stereocomplexes when the polymers are mixed together in solution or melted, so that the molecules are entrapped within the polymer complex as it precipitates or cools. They can also be physically mixed with the stereocomplexes as they are coated onto a device. Alternatively, the bioactive agents can be coupled to the stereocomplexes after formation of the complexes.
• Methods of disposing a stereocomplex coating of the invention over the device and/or over other coating layers include, without limitation, dip-coating, spray coating (including electrospray coating), powder coating, using an ink jet and other techniques known to those skilled in the art.
• Another aspect of the present invention relates to a method for increasing the stability of an implantable medical device coating that involves providing a device body and disposing a coating comprising a stereocomplex of poly(D-lactic acid) and poly(L-lactic acid) over the device body.
• the device body can be a stent.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Epidemiology (AREA)
• Oral & Maxillofacial Surgery (AREA)
• Transplantation (AREA)
• Medicinal Chemistry (AREA)
• Dermatology (AREA)
• Chemical & Material Sciences (AREA)
• Heart & Thoracic Surgery (AREA)
• Surgery (AREA)
• Vascular Medicine (AREA)
• Materials For Medical Uses (AREA)

Priority Applications (2)

Applications Claiming Priority (2)

Publications (2)

Family

ID=40637707

Family Applications (1)

Country Status (4)

Families Citing this family (12)

Citations (1)

Family Cites Families (13)

• 2008
  • 2008-03-20 US US12/052,452 patent/US8377116B2/en not_active Expired - Fee Related
• 2009
  • 2009-03-17 EP EP09722969.4A patent/EP2268329B1/en not_active Not-in-force
  • 2009-03-17 WO PCT/US2009/037375 patent/WO2009117398A2/en not_active Ceased
  • 2009-03-17 JP JP2011500894A patent/JP5500397B2/ja active Active

Patent Citations (1)

Also Published As

Similar Documents

Legal Events